Top-Rated StocksTop-RatedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free RARE Stock Alerts $43.85 -0.43 (-0.97%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$42.73▼$44.0050-Day Range$42.31▼$53.6952-Week Range$31.52▼$54.98Volume470,806 shsAverage Volume758,706 shsMarket Capitalization$3.61 billionP/E RatioN/ADividend YieldN/APrice Target$88.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ultragenyx Pharmaceutical alerts: Email Address Ultragenyx Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside100.9% Upside$88.08 Price TargetShort InterestBearish5.32% of Shares Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment0.32Based on 10 Articles This WeekInsider TradingSelling Shares$1.65 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.36) to ($5.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.32 out of 5 starsMedical Sector101st out of 907 stocksPharmaceutical Preparations Industry35th out of 422 stocks 4.5 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.32% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 11.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 2.4 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ultragenyx Pharmaceutical this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,645,983.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.36) to ($5.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 13.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Read More RARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RARE Stock News HeadlinesApril 25, 2024 | globenewswire.comUltragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateApril 24, 2024 | nasdaq.comFirst Week of RARE June 21st Options TradingApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)April 23, 2024 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at Royal Bank of CanadaApril 22, 2024 | markets.businessinsider.comForecasting The Future: 11 Analyst Projections For Ultragenyx PharmaceuticalApril 19, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 17, 2024 | americanbankingnews.comUltragenyx Pharmaceutical's (RARE) "Neutral" Rating Reaffirmed at WedbushApril 16, 2024 | americanbankingnews.comUltragenyx Pharmaceutical (RARE) Set to Announce Earnings on WednesdayApril 15, 2024 | msn.comWhy Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionApril 15, 2024 | markets.businessinsider.comUltragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick FactsApril 15, 2024 | finance.yahoo.comUltragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102April 12, 2024 | globenewswire.comUltragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeApril 12, 2024 | finanznachrichten.deUltragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingApril 12, 2024 | globenewswire.comUltragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingApril 7, 2024 | cnn.comUltragenyx Pharmaceutical, Inc.April 5, 2024 | markets.businessinsider.comExpert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 AnalystsMarch 22, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 22, 2024 | money.usnews.comUltragenyx Pharmaceutical Inc.March 18, 2024 | markets.businessinsider.comAnalyst Scoreboard: 8 Ratings For Ultragenyx PharmaceuticalMarch 16, 2024 | finance.yahoo.comRARE Apr 2024 50.000 putMarch 15, 2024 | msn.com3 Best Stocks to Buy Now, 3/15/2024, According to Top AnalystsMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Cannabist Company Holdings (OtherCBSTF)March 12, 2024 | finance.yahoo.comInsider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...March 11, 2024 | msn.comWhat’s next for AAV gene therapies in 2024?See More Headlines Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,276Year Founded2010Price Target and Rating Average Stock Price Target$88.08 High Stock Price Target$133.00 Low Stock Price Target$48.00 Potential Upside/Downside+101.6%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($8.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-606,640,000.00 Net Margins-139.70% Pretax Margin-140.12% Return on Equity-369.54% Return on Assets-44.74% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.49 Sales & Book Value Annual Sales$434.25 million Price / Sales8.28 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book13.04Miscellaneous Outstanding Shares82,300,000Free Float76,704,000Market Cap$3.60 billion OptionableOptionable Beta0.65 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Emil D. Kakkis M.D. (Age 64)Ph.D., Founder, President, CEO & Director Comp: $1.37MMr. John Richard Pinion II (Age 58)Chief Quality Operations Officer & Executive VP of Translational Sciences Comp: $806.19kMr. Erik Harris (Age 53)Executive VP & Chief Commercial Officer Comp: $848.24kMr. Howard Horn (Age 46)Executive VP of Corporate Strategy & CFO Mr. Theodore A. Huizenga (Age 53)Senior VP, Corporate Controller & Principal Accounting Officer Ms. Danielle KeatleySenior Director of Investor Relations & Corporate CommunicationsMs. Karah Herdman Parschauer J.D. (Age 46)Chief Legal Officer & Executive VP of Corporate Affairs Comp: $595.01kMr. Ernie W. Meyer (Age 59)Chief Human Resources Officer & Executive VP Mr. Thomas R. Kassberg (Age 64)Chief Business Officer & Executive VP Comp: $714.84kMr. Vimal Srivastava (Age 59)Senior Vice President of Business Development & Alliance Management More ExecutivesKey CompetitorsCymaBay TherapeuticsNASDAQ:CBAYInsmedNASDAQ:INSMPrestige Consumer HealthcareNYSE:PBHAxsome TherapeuticsNASDAQ:AXSMAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 4,500 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Sold 367 shares on 4/24/2024Ownership: 0.173%Eric CrombezSold 142 sharesTotal: $6,262.20 ($44.10/share)Allspring Global Investments Holdings LLCBought 1,339 shares on 4/18/2024Ownership: 0.004%Hennion & Walsh Asset Management Inc.Bought 14,159 shares on 4/17/2024Ownership: 0.060%View All Insider TransactionsView All Institutional Transactions RARE Stock Analysis - Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RARE shares. View RARE analyst ratings or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price target for 2024? 12 equities research analysts have issued 12 month price objectives for Ultragenyx Pharmaceutical's shares. Their RARE share price targets range from $48.00 to $133.00. On average, they anticipate the company's stock price to reach $88.08 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts. How have RARE shares performed in 2024? Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of the year. Since then, RARE shares have decreased by 8.3% and is now trading at $43.85. View the best growth stocks for 2024 here. When is Ultragenyx Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RARE earnings forecast. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.65) by $0.13. The biopharmaceutical company had revenue of $127.39 million for the quarter, compared to analysts' expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 369.54% and a negative net margin of 139.70%. Ultragenyx Pharmaceutical's revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.16) earnings per share. What ETFs hold Ultragenyx Pharmaceutical's stock? ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Tema Cardiovascular and Metabolics ETF (HRTS), Motley Fool Mid-Cap Growth ETF (TMFM), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and Simplify Health Care ETF (PINK). What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $504.3 million. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.17%), Hennion & Walsh Asset Management Inc. (0.06%), Woodstock Corp (0.01%), Simplex Trading LLC (0.00%), Allspring Global Investments Holdings LLC (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Eric Crombez, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RARE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.